Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

Abstract

While these data must still not be interpreted as evidence of neuroprotection, they nevertheless provide strong encouragement for the further study of this drug as a potential disease modifying agent in Parkinson's disease.